The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
Check out some of the stocks that will react on the basis of their numbers in the near term.
The worms were detected in Elferri capsules, manufactured by a Goan company. The FDA has initiated a probe.
Global generic drugs producer Sandoz has opened its third plant in India at Navi Mumbai with annual production capacity of one billion tablets and capsules.
The presence of ants was detected at Alibag in Maharashtra and subsequently a complaint was lodged with the Food and Drug Administration authorities.
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis.
Ranbaxy Laboratories on Friday said it has received tentative approval from US Food and Drug Administration to manufacture and market Ofloxacin, the generic version of Ortho Mcneil Pharmaceutical Inc's Floxin.
Facing arbitration claims by Daiichi Sankyo, Ranbaxy's former Indian promoters - Malvinder Mohan Singh, his brother Shivinder Mohan Singh and family - are counting on certain clauses in the share purchase agreement (SPA) signed with the Japanese company on June 11, 2008, to claim immunity from damages.
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments
Dinesh Thakur is famous for exposing Ranbaxy safety problems
Goa on Sunday joined several other states in banning the sale of Nestle's instant noodle brand 'Maggi' which is at the centre of a raging nationwide row over food safety concerns.
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
Experts question Nestle's silence over Maggi controversy.
We are surrounded by food that is contaminated, adulterated and does not meet Indian safety and packaging standards, says Abheet Singh Sethi/IndiaSpend.com.
Punishing brand ambassadors shows that the government is only interested in going after the low hanging fruit, says Tanmaya Nanda.
Indian drug maker Alembic Ltd plans to expand its bulk drugs business in the United States by joining hands with US formulations makers, the Bombay Stock Exchange said on Thursday.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
Kapiva's plans to introduce allopathy-like doses of ayurvedic remedies for the millennial consumer finds traction.
Lupin was the top gainer after the USFDA cleared its Goa facility
Daiichi alleged that Singh brothers had concealed and misrepresented critical information concerning US Food and Drug Administration and Department of Justice investigations into Ranbaxy
Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.
The 50-share NSE Nifty stayed in the positive zone and retook the 9,900-mark to hit a high of 9,905.05 as buying paced up towards the fag end. It settled higher by 72.45 points, or 0.74 per cent, at 9,899.60.
The introduction of e-pharmacy, to protect the interest of a handful of players, would hamper the interest of 800,000 chemists and 80 lakh workers and their families
The company did not comply to the 'good manufacturing practice' norms.
In the Sensex pack, ICICI Bank emerged as the top gainer by rising 0.97 per cent, while Tata Steel advanced 0.92 per cent.
The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.
Lupin will fund the buy through $100 mn cash reserves and a bridge loan.
Maggi banned in Delhi for 15 days.
The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.
The drug is licensed to Ranbaxy Laboratories from Cipher Pharmaceuticals Inc of Mississauga, Ontario. It is currently protected by two issued patents listed in the FDA's approved drug products list, which expire in September 2021, the company said in a statement.
A widening probe by US authorities involving top drug companies following complaints of price fixing of generics was a point of worry for the participants, said analysts.
